RESUMEN

OBJECTIVES: Metastatic prostate cancer is the most common malignant cancer and the second leading cause of death due to various types of cancer among men after lung cancer. This study aimed to analyze the cost-effectiveness of triptorelin, goserelin, and leuprolide in the treatment of the patients with metastatic prostate cancer from the societal perspective in Iran in 2020. METHODS: This is a cost-effectiveness study in which a 20-year Markov transition modeling was applied. In this study, local cost and quality-of-life data of each health state were gathered from cohort of patients. The TreeAge pro 2020 and Microsoft Excel 2016 software were used to simulate cost-effectiveness of each treatment in the long term. The one-way and probabilistic sensitivity analyses were also performed to measure robustness of the model outputs. RESULTS: The findings indicated that the mean costs and utility gained over a 20-year horizon for goserelin, triptorelin, and leuprolide treatments were $ 13 539.13 and 6.365 quality-adjusted life-years (QALY), $ 18 124.75 and 6.658 QALY, and $ 26 006.92 and 6.856 QALY, respectively. Goserelin was considered as a superior treatment option, given the estimated incremental cost-effectiveness ratio. The one-way and probabilistic sensitivity analyses confirmed the robustness of the study outcomes. CONCLUSIONS: According to the results of the present study, goserelin was the most effective and cost-effective strategy versus 2 other options. It could be recommended to policy makers of the Iran healthcare system to prioritize it in clinical guidelines and reimbursement policies.

Asunto(s)

Antineoplásicos Hormonales , Goserelina , Leuprolida , Neoplasias de la Próstata , Años de Vida Ajustados por Calidad de Vida , Pamoato de Triptorelina , Anciano , Humanos , Masculino , Persona de Mediana Edad , Antineoplásicos Hormonales/uso terapéutico , Antineoplásicos Hormonales/economía , Análisis de Costo-Efectividad , Goserelina/uso terapéutico , Goserelina/economía , Goserelina/administración & dosificación , Irán , Leuprolida/uso terapéutico , Leuprolida/economía , Leuprolida/administración & dosificación , Cadenas de Markov , Metástasis de la Neoplasia , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/economía , Calidad de Vida , Pamoato de Triptorelina/uso terapéutico , Pamoato de Triptorelina/economía , Pamoato de Triptorelina/administración & dosificación

RESUMEN

BACKGROUND: CDK4/6 inhibitors have shown promising results for treating advanced breast cancer (ABC) and are routinely used in Singapore. In view of their high costs, it is important to assess their relative value compared to existing standards of care in the local setting. AIMS: This study evaluates the cost-effectiveness of adding ribociclib to goserelin and a nonsteroidal aromatase inhibitor or tamoxifen as initial therapy for premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC in Singapore. METHODS: A partitioned survival model with four health states (progression-free on first-line treatment, progression-free on second-line treatment, progressed disease, and death) was developed from a healthcare system perspective over a 10-year time horizon. Key clinical inputs were derived from the MONALEESA-7 trial, and survival curves were extrapolated beyond the trial period. Health state utilities were derived from the literature and direct medical costs were obtained from local public healthcare institutions. A discount rate of 3% was applied to both costs and outcomes. One-way deterministic and probabilistic sensitivity analyses were conducted to explore uncertainties. RESULTS: The base-case analysis resulted in an incremental cost-effectiveness ratio (ICER) of SGD197, 667 per quality-adjusted life-year. Sensitivity analyses showed that the ICER was sensitive to the survival parametric distribution, ribociclib price, time horizon, and utility weights used. Even when these were varied, ICERs remained high and not cost-effective in the local context. CONCLUSION: At its current price, adding ribociclib to endocrine therapy is unlikely to be cost-effective in Singapore for HR+, HER2- ABC. Results from this study are useful to inform future funding decisions for CDK4/6 inhibitors alongside other factors including clinical effectiveness, safety, and budget impact considerations.

Asunto(s)

Aminopiridinas/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama/terapia , Costos de los Medicamentos/estadística & datos numéricos , Purinas/administración & dosificación , Aminopiridinas/economía , Protocolos de Quimioterapia Combinada Antineoplásica/economía , Inhibidores de la Aromatasa/administración & dosificación , Inhibidores de la Aromatasa/economía , Neoplasias de la Mama/economía , Neoplasias de la Mama/mortalidad , Quimioterapia Adyuvante , Ensayos Clínicos Fase III como Asunto , Femenino , Estudios de Seguimiento , Goserelina/administración & dosificación , Goserelina/economía , Humanos , Estimación de Kaplan-Meier , Mastectomía , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Terapia Neoadyuvante/métodos , Premenopausia , Supervivencia sin Progresión , Purinas/economía , Años de Vida Ajustados por Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Singapur/epidemiología , Tasa de Supervivencia , Resultado del Tratamiento

RESUMEN

The TEXT and SOFT trials concluded that an aromatase inhibitor (AI) with ovarian ablation (OA) yields a higher 5-year disease-free survival than tamoxifen alone in premenopausal ER+ high-risk early breast cancer. However, the long-term health consequences and costs of OA, either by GnRH agonist or oophorectomy, have not been evaluated. The objective was to conduct a cost-effectiveness analysis comparing tamoxifen to OA with AI. Markov Monte Carlo simulation model estimated the costs and benefits of 3 endocrine strategies: (1) tamoxifen; (2) GnRH agonist with AI (GnRHa-AI); (3) bilateral salpingo-oophorectomy with AI (BSO-AI). Effectiveness was measured in life expectancy gain (years), and costs were averaged over a lifetime (USD 2015). Adverse events and deaths from each strategy were modeled in the United States population over a time horizon of 40 years. For women without prior chemotherapy (low-risk), tamoxifen alone was more effective (18.03 years) and less costly ($1566) than GnRHa-AI (17.66 years, $93,692) or BSO-AI (17.63 years, $25,892). For those with prior chemotherapy (high-risk), BSO-AI was more costly but more effective (16.78 years, $25,368) than tamoxifen alone (16.55 years, $1523) with an ICER of $102,290, while GnRHa-AI yielded an ICER of $443,376. The simulation estimated 787 and 577 deaths attributable to OA among 9320 high-risk women after BSO-AI and GnRHa-AI, respectively. There may be a role for ovarian ablation in premenopausal women with ER+ high-risk early breast cancer; however, this analysis raises concerns about the long-term health consequences of ovarian ablation and the potential effects on overall survival.

Asunto(s)

Antineoplásicos Hormonales/economía , Neoplasias de la Mama/tratamiento farmacológico , Goserelina/economía , Ovariectomía/economía , Tamoxifeno/economía , Antineoplásicos Hormonales/uso terapéutico , Análisis Costo-Beneficio , Supervivencia sin Enfermedad , Femenino , Goserelina/uso terapéutico , Humanos , Cadenas de Markov , Persona de Mediana Edad , Modelos Económicos , Premenopausia , Análisis de Supervivencia , Tamoxifeno/uso terapéutico , Resultado del Tratamiento

RESUMEN

BACKGROUND: Increased health care costs have made it incumbent on health-care facilities and physicians to demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prostate cancer, few have compared the cost-effectiveness of adjuvant goserelin to adjuvant chemotherapy alone in premenopausal breast cancer. METHODS: In this retrospective study at one hospital, the records of 152 patients with stage Ia to IIIa ER + breast cancer who received goserelin or chemotherapy were reviewed. Survival analysis was assessed by the Kaplan-Meier method. Patients were interviewed to evaluate their quality of life using the European Organization for Research and Treatment Quality of Life questionnaire (EORTC-QLQ-C30, version 4.0), and to obtain the utility value by the standard gamble (SG) and visual scale (VS) methods. Total medical cost was assessed from the (National Health Insurance) NHI payer's perspective. RESULTS: Survival at 11 years was significantly better in the groserelin group (P < 0.0012). The lifetime lost was lower in the goserelin group (42 months vs. 66 months). The quality adjusted survival (QAS) of patients who received goserelin was longer (122.5 ± 6.3 vs. 112.2 ± 6.7 months). Total expenses of goserelin were more than cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy regimes, but less than docetaxel, epirubicin (TE) or docetaxel, epirubicin, cyclophosphamide (TEC) regimes. The quality-adjusted life-year was higher in the goserelin group. CONCLUSIONS: Goserelin therapy results in better survival and higher utility-weighted life-years, and is more cost-effective than TC or TEC chemotherapy.

Asunto(s)

Antineoplásicos Hormonales/economía , Neoplasias de la Mama/tratamiento farmacológico , Quimioterapia Adyuvante/economía , Goserelina/economía , Premenopausia , Adulto , Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/mortalidad , Análisis Costo-Beneficio , Femenino , Goserelina/uso terapéutico , Costos de la Atención en Salud , Estado de Salud , Humanos , Persona de Mediana Edad , Calidad de Vida , Estudios Retrospectivos , Tasa de Supervivencia

RESUMEN

OBJECTIVES: Luteinizing hormone-releasing hormone (LHRH) agonists represent one of the main cost factors in the management of patients with metastatic prostate cancer. We compared the cost-effectiveness of the five different 3-month formulations of LHRH agonists currently available for advanced prostate cancer in Italy, because these differ both in their capacity to suppress testosterone and in their acquisition costs. METHODS: A probabilistic, patient-level simulation model was developed to compare the cost-effectiveness, from the perspective of the Italian National Health Service (INHS), of leuprorelin 11.25 mg and 22.5 mg, triptorelin 11.25 mg, buserelin 9.9 mg, and goserelin 10.8 mg. The model incorporated testosterone-dependent progression-free and cancer-specific survival functions, LHRH agonist effectiveness data, and national costs and tariffs. Cox's proportional hazard models were used to compute total and progression-free survival functions based on clinical data from 129 patients with metastatic prostate cancer treated in an Italian center. Bayesian random effects models were employed to summarize evidence from published literature on testosterone suppression obtained with the available LHRH agonists. RESULTS: Estimated total survival was ≈5 years, with a maximum difference between treatment options of ≈2 months. There was a mean difference of almost €2,500 in lifetime total costs between the least costly option (leuprorelin 22.5 mg) and the most expensive (goserelin). In the incremental cost-effectiveness analysis, leuprorelin 22.5 mg dominated all alternatives except buserelin, which had an incremental cost-effectiveness ratio versus leuprorelin 22.5 mg of ≈€12,000 per life-month gained. CONCLUSIONS: Based on modelling with meta-analysis of comparative survival data, leuprorelin 22.5 mg was the most cost-effective treatment of the available depot formulation LHRH agonists.

Asunto(s)

Antineoplásicos Hormonales/economía , Costos de los Medicamentos , Hormona Liberadora de Gonadotropina/economía , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Antineoplásicos Hormonales/administración & dosificación , Buserelina/administración & dosificación , Buserelina/economía , Análisis Costo-Beneficio , Árboles de Decisión , Hormona Liberadora de Gonadotropina/administración & dosificación , Goserelina/administración & dosificación , Goserelina/economía , Humanos , Italia , Leuprolida/administración & dosificación , Leuprolida/economía , Masculino , Modelos Econométricos , Modelos de Riesgos Proporcionales , Neoplasias de la Próstata/economía , Análisis de Supervivencia , Pamoato de Triptorelina/administración & dosificación , Pamoato de Triptorelina/economía

Asunto(s)

Neoplasias de la Mama/terapia , Técnicas de Apoyo para la Decisión , Árboles de Decisión , Antagonistas de Estrógenos/economía , Goserelina/economía , Laparoscopía/economía , Neoplasias de la Mama/metabolismo , Análisis Costo-Beneficio , Antagonistas de Estrógenos/uso terapéutico , Femenino , Goserelina/uso terapéutico , Humanos , Ovariectomía/economía , Ovariectomía/métodos , Premenopausia , Años de Vida Ajustados por Calidad de Vida , Receptores de Estrógenos/metabolismo

Asunto(s)

Antagonistas de Andrógenos/economía , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/economía , Antineoplásicos Hormonales/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Hormona Liberadora de Gonadotropina/agonistas , Medicare , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Quimioterapia Adyuvante , Prescripciones de Medicamentos/economía , Goserelina/economía , Goserelina/uso terapéutico , Recursos en Salud/estadística & datos numéricos , Humanos , Leuprolida/economía , Leuprolida/uso terapéutico , Masculino , Medicare/legislación & jurisprudencia , Neoplasias Hormono-Dependientes/economía , Neoplasias de la Próstata/economía , Programa de VERF , Estados Unidos

RESUMEN

BACKGROUND: The ABCSG-12 trial investigated the efficacy of gonadotropin-releasing hormone (GnRH)analogs in combination with tamoxifen or anastrozole + or - zoledronic acid (4 mg, q6m for 3 years) in 1,803 premenopausal women with hormone receptor-positive (HR+) breast cancer. After 48 months of follow-up, there was a 36% improvement in the disease-free survival (DFS) (recurrence-free survival 35%) using zoledronic acid. Based on these data, the costutility of zoledronic acid was calculated for the German healthcare system. MATERIALS AND METHODS: Costs of surveillance, adverse effects, recurrence, contralateral breast cancer, metastasis, and end-of-life care were determined based on the Einheitlicher Bewertungsmabetastab (EBM 2009) and the diagnosis-related groups (DRG) system. Utilities were surveyed with a questionnaire (n = 95). Estimation of the cost-utility was made by calculating the incremental costeffectiveness ratio (ICER) per quality-adjusted life year (QALY), using a Markov model. RESULTS: Including zoledronic acid as adjuvant therapy for 3 years resulted in total costs of euro 2,262. The use of zoledronic acid is dominant when clinical efficacy and quality of life are taken into consideration (- euro 45.83/QALY) (95% confidence interval (CI) - euro 1,838 to E 2,375; 0.02-0.41 QALY). The sensitivity analyses present with a probability of 90% that the cost per QALY gained are

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/economía , Conservadores de la Densidad Ósea/economía , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/economía , Difosfonatos/economía , Costos de los Medicamentos/estadística & datos numéricos , Goserelina/economía , Imidazoles/economía , Programas Nacionales de Salud/economía , Nitrilos/economía , Tamoxifeno/economía , Triazoles/economía , Anastrozol , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Conservadores de la Densidad Ósea/efectos adversos , Conservadores de la Densidad Ósea/uso terapéutico , Neoplasias de la Mama/mortalidad , Análisis Costo-Beneficio , Difosfonatos/efectos adversos , Difosfonatos/uso terapéutico , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Alemania , Goserelina/uso terapéutico , Humanos , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Cadenas de Markov , Método de Montecarlo , Estudios Multicéntricos como Asunto , Neoplasias Primarias Múltiples/tratamiento farmacológico , Neoplasias Primarias Múltiples/economía , Neoplasias Primarias Múltiples/mortalidad , Nitrilos/uso terapéutico , Años de Vida Ajustados por Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Tamoxifeno/uso terapéutico , Triazoles/uso terapéutico , Ácido Zoledrónico

Asunto(s)

Planes de Seguros y Protección Cruz Azul , Defensa del Consumidor/legislación & jurisprudencia , Costos de los Medicamentos/legislación & jurisprudencia , Industria Farmacéutica/legislación & jurisprudencia , Fraude/legislación & jurisprudencia , Antineoplásicos Hormonales/economía , Planes de Seguros y Protección Cruz Azul/legislación & jurisprudencia , Goserelina/economía , Humanos , Massachusetts

RESUMEN

BACKGROUND: In Radiation Therapy Oncology Group (RTOG) trial 92-02, after men received neoadjuvant hormone cytoreduction and radiotherapy for locally advanced prostate carcinoma, they were randomized to receive either 2 years of long-term androgen-deprivation (LTAD) or no further treatment (short-term androgen-deprivation [STAD]). The specific objective of the current study was to determine whether LTAD was a cost-effective treatment for patients with locally advanced prostate carcinoma. METHODS: The cost-effectiveness of LTAD was tested using a Markov model that was designed using proprietary software. The analysis took a payor's perspective. Unit costs were obtained by estimation using a global Medicare fee schedule. Costs and outcomes were discounted by 3%. Distributions were sampled at random from the treatment utilities, transition probabilities, and costs using a second-order Monte Carlo simulation technique. RESULTS: The expected mean cost was 32,564 dollars for LTAD compared with 33,039 dollars for STAD after accounting for the additional cost of salvage treatment for men who were treated with STAD. The mean number of quality-adjusted life years (QALYs) for men who received LTAD was 4.13 QALYs compared with a mean of 3.68 QALYs for men who received STAD. The cost-effectiveness acceptability curve analysis showed a 91% probability that LTAD was cost-effective compared with STAD. Although overall survival was similar in the LTAD and STAD groups, the patients who received LTAD experienced gains in QALYs and had lower costs, because LTAD prevented biochemical failure and the necessitating salvage hormone therapy. CONCLUSIONS: The current analysis showed that LTAD was cost-effective for the entire population studied in RTOG trial 92-02.

Asunto(s)

Adenocarcinoma/economía , Neoplasias de la Próstata/economía , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/radioterapia , Antagonistas de Andrógenos/economía , Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/economía , Antineoplásicos Hormonales/uso terapéutico , Terapia Combinada , Análisis Costo-Beneficio , Flutamida/economía , Flutamida/uso terapéutico , Goserelina/economía , Goserelina/uso terapéutico , Humanos , Masculino , Cadenas de Markov , Método de Montecarlo , Terapia Neoadyuvante/economía , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Años de Vida Ajustados por Calidad de Vida , Radioterapia Conformacional/economía , Ensayos Clínicos Controlados Aleatorios como Asunto

Asunto(s)

Industria Farmacéutica/economía , Fraude/economía , Antineoplásicos Hormonales/economía , Delaware , Industria Farmacéutica/legislación & jurisprudencia , Fraude/legislación & jurisprudencia , Goserelina/economía

RESUMEN

To quantify the incremental costs and outcomes of using long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. The cost of radiotherapy for prostate cancer has been calculated using an activity-costing model. The total cost of administering adjuvant hormonal therapy for 3 years is based on local pharmacy charges plus typical physician billing fees and additional laboratory costs. Outcome data were obtained from the published EORTC 22,863 randomized trial comparing treatment of locally advanced prostate cancer with radiotherapy alone or in combination with 3 years of adjuvant goserelin. Using this information, the cost-effectiveness of adjuvant goserelin was calculated and expressed in terms of dollars per life-years (LY) gained. The total institutional costs of radiotherapy are $9000 Cdn. and the additional costs of providing adjuvant goserelin for 3 years are approximately $19,800 CDN. The improvement in outcome with the use of adjuvant goserelin was estimated to be 1.2 LY per patient treated, giving a cost-effectiveness ratio of $16,500 Cdn ($11,000 US) per LY from an institutional perspective. Our sensitivity analysis confirms the robustness of our findings since even in our "worst case" scenario the cost-effectiveness ratio was estimated to be $21,600 Can ($14,400 US) per LY gained. This figure is still below $50,000 US per LY gained which is the quoted current standard for cost-effectiveness. This analysis demonstrates that the use of long-term adjuvant goserelin for locally advanced prostate cancer provides substantial benefit at an acceptable cost.

Asunto(s)

Adenocarcinoma/economía , Antineoplásicos Hormonales/economía , Quimioterapia Adyuvante/economía , Goserelina/economía , Neoplasias de la Próstata/economía , Teleterapia por Radioisótopo/economía , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , Adenocarcinoma/radioterapia , Antineoplásicos Hormonales/uso terapéutico , Gastos de Capital , Terapia Combinada/economía , Análisis Costo-Beneficio , Costos de los Medicamentos , Honorarios Médicos , Honorarios Farmacéuticos , Goserelina/uso terapéutico , Costos de Hospital , Humanos , Masculino , Ontario , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/radioterapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Análisis de Supervivencia , Resultado del Tratamiento

RESUMEN

The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival time, but with censored survival data, the true survival time for all the subjects is not known, so the mean is not defined.A possible solution to this estimation problem is illustrated by a retrospective cost-effectiveness analysis of the addition of hormonal therapy to standard radiotherapy for patients with locally advanced prostate cancer. A recently proposed method is used to approach the problem caused by censored cost data, and the impact of uncertainty is assessed by bootstrap resampling techniques. Mean survival time is estimated by a restricted means analysis with the time point of restriction determined by statistical criteria. When average total costs and mean survival time is evaluated at this time point of restriction, the result is that the combined therapy (radiotherapy plus hormonal therapy) increases mean survival time by about 1 year, while reducing the costs per patient for the French health insurance system by 12 700 FF. The time point of restriction may also be determined by other criteria and mean survival time may be estimated by extrapolating the survival curves by means of various parametric survival distributions. We show that the exact results of the economic evaluation are decisively determined by the restriction time point chosen and the approach taken to estimate mean survival time.

Asunto(s)

Antineoplásicos Hormonales/uso terapéutico , Quimioterapia Adyuvante/economía , Goserelina/uso terapéutico , Costos de la Atención en Salud/estadística & datos numéricos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Años de Vida Ajustados por Calidad de Vida , Antineoplásicos Hormonales/economía , Análisis Costo-Beneficio , Costos de los Medicamentos/estadística & datos numéricos , Francia , Goserelina/economía , Humanos , Masculino , Modelos Estadísticos , Estadificación de Neoplasias , Pronóstico , Modelos de Riesgos Proporcionales , Neoplasias de la Próstata/economía , Neoplasias de la Próstata/patología , Análisis de Supervivencia , Resultado del Tratamiento

RESUMEN

We present a retrospective cost-effectiveness analysis using data from a randomised controlled trial (EORTC 22863) of the addition of early hormonal therapy with a luteinising hormone-releasing hormone (LHRH) analogue to radiotherapy in the treatment of patients with locally advanced prostate cancer. Data on the use of medical resources were extracted from the hospital charts of 90 patients recruited into the trial by one French hospital. Costs are assessed from the viewpoint of the French healthcare financing system and adjusted for censoring. Expected costs per patient of each treatment is related to the expected outcome, mean survival time, estimated by a restricted means analysis. The time point of restriction is determined by statistical criteria. In the base case analysis with a cut-off time point at 8.58 years, the combined therapy group (COMB) had a gain in mean survival time of 1.06 years (7.05 versus 5.99 years) and a reduction of average total costs of 12700 French francs (FF) (58300 FF versus 71000 FF). The analysis of uncertainty uses bootstrap techniques with 5000 replicates to examine the joint distribution of cost and survival outcomes. In 76% of the cases, COMB results in longer mean survival time and lower costs than the radiotherapy group (RT). In cases where COMB therapy raises costs (13% of the cases), it is rarely by more than 20000 FF per patient, no matter the size of the associated survival gain. It is thus highly likely that COMB should be considered a cost-effective option compared with RT for these patients. The exact result of the economic evaluation is decisively determined by the restriction time point selected for the determination of mean survival time, partly also because the average total costs of the two treatments develop entirely differently as a function of the survival time.

Asunto(s)

Antineoplásicos Hormonales/economía , Antineoplásicos Hormonales/uso terapéutico , Goserelina/economía , Goserelina/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Terapia Combinada , Análisis Costo-Beneficio/métodos , Estudios de Seguimiento , Francia , Costos de la Atención en Salud , Humanos , Masculino , Neoplasias de la Próstata/economía , Neoplasias de la Próstata/radioterapia , Estudios Retrospectivos , Tasa de Supervivencia

RESUMEN

BACKGROUND: We have today two treatment alternatives (orchiectomy or LHRH-analogue) in metastatic prostate cancer offering the same expectations of survival. This study documents the quality of life (QoL) and cost-effectiveness of these alternatives. PATIENTS AND METHODS: 65 consecutive patients treated at the University Hospital of Tromsø (UHT), Norway, between 1994 and 1999 were registered. At evaluation, 45 patients (LHRH-analogue--15 patients, orchiectomy--30 patients) were alive and included in the QoL-study (EORTC QLQ C-30, QoL 15D). 45 patients were followed-up at the UHT and included in the cost-analysis. Costs were calculated for a 36-month interval and converted to British pounds (1 Pound = 13 NOK). A 5% d.r. was employed. RESULTS: The mean QoL (15D) was 76.4 (orchiectomy) and 72 (LHRH) (0-100 scale). Constipation, urinating problems, fatigue, pain and loss of sexual functioning were the dominant symptoms. The treatment costs per patient treated were 8,895 Pounds (orchiectomy) and 10,937 Pounds (LHRH-analogue). The crossover in cost was located at 25 months. A sensitivity analysis varying discount rate (0-10%), drug charges (25-50% off) and treatment time (12-18 months) did not alter the conclusion. CONCLUSION: Orchiectomy is the treatment of choice when life expectancy is more than two years.

Asunto(s)

Adenocarcinoma/terapia , Antineoplásicos Hormonales/uso terapéutico , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Goserelina/uso terapéutico , Antagonistas de Hormonas/uso terapéutico , Orquiectomía , Neoplasias de la Próstata/terapia , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/economía , Adenocarcinoma/psicología , Adenocarcinoma/cirugía , Anciano , Antineoplásicos Hormonales/efectos adversos , Antineoplásicos Hormonales/economía , Análisis Costo-Beneficio , Costos de los Medicamentos , Estudios de Seguimiento , Goserelina/efectos adversos , Goserelina/economía , Antagonistas de Hormonas/efectos adversos , Antagonistas de Hormonas/economía , Costos de Hospital , Humanos , Esperanza de Vida , Masculino , Persona de Mediana Edad , Programas Nacionales de Salud , Noruega/epidemiología , Orquiectomía/economía , Orquiectomía/psicología , Servicio Ambulatorio en Hospital/economía , Servicio Ambulatorio en Hospital/estadística & datos numéricos , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/economía , Neoplasias de la Próstata/psicología , Neoplasias de la Próstata/cirugía , Calidad de Vida , Estudios Retrospectivos

RESUMEN

OBJECTIVE: To analyse the cost, effectiveness and cost effectiveness of two endometrial thinning agents prior to laser ablation for dysfunctional uterine bleeding: danazol and goserelin. SETTING: A district general hospital. DESIGN: A retrospective cost effectiveness analysis, from the perspective of the health service, based on data from an open, randomised, parallel group comparative study of 160 pre-menopausal women with dysfunctional uterine bleeding. METHODS: Within the trial, length of operation and duration of hospital stay was recorded for each woman. Resource use due to complications of surgery and adverse drug events was evaluated by one of the authors (R.G.). Additional surgery after completion of the study was collected using a postal questionnaire which was distributed to every woman who had undergone surgery. Resource use was costed using detailed unit costs from a specific NHS trust and from published sources. A cost effectiveness analysis was undertaken relating differential cost to differential rates of amenorrhoea at women's last point of follow up. RESULTS: Information on amenorrhoea was available from 138 women, of whom 111 had completed the questionnaire to indicate longer term follow up. Women who did not complete the clinical trial were not included in this economic evaluation. On average, women randomised to goserelin spent less time in theatre and on the ward. Based on longer term follow up, rates of retreatment were similar in the two groups. The mean (SD) health service cost of women in the goserelin group was pound sterling 323.84 (pound sterling 309.94), compared with pound sterling 243.45 (pound sterling 265.23) in the danazol group; median (range) costs were pound sterling 220.29 (pound sterling 191-pound sterling 2127) and pound sterling 159.76 (pound sterling 140-pound sterling 1426) in the two groups, respectively. These costs were significantly higher for goserelin (P = 0.0001). The goserelin group also had a higher rate of amenorrhoea (38.8% vs 28.6%, P = 0.23). Based on mean differences in cost, the incremental cost of goserelin per additional woman with amenorrhoea was pound sterling 788; based on median differences in cost the ratio was pound sterling 590. CONCLUSIONS: The shorter duration in theatre and stay in hospital provided a modest offset of the higher acquisition cost of goserelin, but the overall cost of management remained significantly higher than managing women with danazol. The rates of amenorrhoea indicated that goserelin was more effective at 24 weeks and approximately two years after surgery, although statistical significance was only achieved at 24 weeks. The economic impact of women withdrawn from treatment was not considered, but sensitivity analysis indicates that these women may have had a large effect on the overall result of this study. Purchasers will need to decide whether the additional cost of management with goserelin is justified by the increased rates of amenorrhoea and the reduced withdrawals from treatment.

Asunto(s)

Antineoplásicos Hormonales/uso terapéutico , Danazol/uso terapéutico , Antagonistas de Estrógenos/uso terapéutico , Goserelina/uso terapéutico , Hemorragia Uterina/cirugía , Adulto , Análisis Costo-Beneficio , Danazol/economía , Femenino , Goserelina/economía , Humanos , Tiempo de Internación , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Hemorragia Uterina/economía

RESUMEN

BACKGROUND: The study was an audit of patients who attended the Menstrual Disorders Clinic at Glasgow Royal Infirmary over a five year period, and received gonadotrophin-releasing hormone analog (GnRHa). We aimed to identify the clinical indications for the use of GnRHa, and the effect of the latter in terms of symptom resolution and ultimate outcome. We aim to use this information to formulate a strategy for the use of GnRHa by targeting this expensive therapy to those situations where maximum benefit will be achieved. METHODS: A retrospective case review analysis of 201 patients. RESULTS: Thirty-eight percent of women presented with pelvic pain, 33% with disordered menstruation and 26% with premenstrual symptomatology. Overall, 74% of patients reported a beneficial effect of GnRHa. In the non-cyclical pelvic pain group, those patients with adhesions constituted a much greater proportion of those who did not derive benefit from GnRHa than those who did (43% vs. 16%; p<0.05; data not shown). In those patients with disordered menses, there was no difference between the diagnosis in those who did or did not derive benefit from GnRHa. Also with the exception of endometrial preparation prior to ablation and in the correction of anemia, the ultimate outcome was no different in the two groups. Of the patients with premenstrual symptomatology, the greatest proportion of those deriving benefit from GnRHa (41%) ultimately had an operative resolution. CONCLUSIONS: Our results enable us to use GnRHa as a first line in those clinical situations where maximum benefit will be achieved, either in terms of symptom resolution or as a tool to identify the most appropriate therapeutic option. We can therefore rationalize our prescribing both to the benefit of the patient and to our budget.

Asunto(s)

Goserelina/uso terapéutico , Trastornos de la Menstruación/tratamiento farmacológico , Adulto , Análisis Costo-Beneficio , Utilización de Medicamentos/estadística & datos numéricos , Femenino , Goserelina/economía , Humanos , Dolor Pélvico/tratamiento farmacológico , Síndrome Premenstrual/tratamiento farmacológico , Estudios Retrospectivos

RESUMEN

OBJECTIVES: With 184,500 new cases and 39,200 deaths anticipated in 1998, prostate cancer is second only to lung cancer in cancer mortality for men. This report is a systematic review of the evidence from randomized controlled trials on the relative effectiveness of alternative strategies for androgen suppression as treatment of advanced prostate cancer. Three key issues are addressed: (1) the relative effectiveness of the available methods for monotherapy (orchiectomy, luteinizing hormone-releasing hormone [LHRH] agonists, and antiandrogens), (2) the effectiveness of combined androgen blockade compared to monotherapy, and (3) the effectiveness of immediate androgen suppression compared to androgen suppression deferred until clinical progression. Outcomes of interest are overall, cancer-specific, and progression-free survival; time to treatment failure; adverse effects; and quality of life. Two supplementary analyses were conducted for each key question: (1) meta-analysis of overall survival at 2 years (questions 1 and 2) and 5 years (questions 2 and 3), and (2) cost-effectiveness analysis. SEARCH STRATEGY: The MEDLINE, CANCERLIT, and EMBASE databases were searched from 1966 to March 1998, and Current Contents to August 24, 1998, for the terms: leuprolide (Lupron); goserelin (Zoladex); buserelin (Suprefact); flutamide (Eulexin); nilutamide (Anandron, Nilandron); bicalutamide (Casodex); cyproterone acetate (Androcur); diethylstilbestrol (DES); and orchiectomy (castration, orchidectomy). The search was then limited to human studies indexed under the MeSH term "prostatic neoplasms" and by the UK Cochrane Center search strategy for randomized controlled trials. Total yield was 1,477 references. SELECTION CRITERIA: We Reports of efficacy outcomes were limited to randomized controlled trials. Phase II studies that reported on withdrawals from therapy and all studies reporting on quality of life were also included. DATA COLLECTION AND ANALYSIS: The systematic review used a prospectively designed protocol conducted by two independent reviewers, with disagreements resolved by consensus. The meta-analysis combined data on overall survival using a random effects model. The cost-effectiveness analysis used a decision analysis model of advanced prostate cancer with health states and transitions derived from the literature and estimates of effectiveness derived from the meta-analysis. The cost-effectiveness analysis is conducted from a societal perspective, consistent with the guidelines of the U.S. Public Health Service Panel on Cost-Effectiveness in Health and Medicine. MAIN RESULTS: Survival after treatment with an LHRH agonist is equivalent to survival after orchiectomy. The available LHRH agonists are equally effective, and no LHRH agonist is superior to the other when adverse effects are considered. Survival may be somewhat lower with use of a nonsteroidal antiandrogen. There is no statistically significant difference in survival at 2 years between patients treated with combined androgen blockade or monotherapy. Meta-analysis of the limited data available shows a statistically significant difference in survival at 5 years that favors combined androgen blockade. However, the magnitude of this difference is of questionable clinical significance. For the subgroup of patients with good prognosis, there is no statistically significant difference in survival. Adverse effects leading to withdrawal from therapy occurred more often with combined androgen blockade. No evidence is yet available from randomized controlled trials of androgen suppression initiated at prostate-specific antigen (PSA) rise after definitive therapy for clinically localized disease. For patients who are newly diagnosed with locally advanced or asymptomatic metastatic disease, the evidence is insufficient to determine whether primary androgen suppression initiated at diagnosis improves outcomes. (ABSTRACT TRUNCATED)

Asunto(s)

Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Medicina Basada en la Evidencia , Hormona Liberadora de Gonadotropina/agonistas , Orquiectomía , Neoplasias de la Próstata/terapia , Antagonistas de Andrógenos/economía , Antineoplásicos Hormonales/economía , Análisis Costo-Beneficio , Goserelina/economía , Goserelina/uso terapéutico , Humanos , Leuprolida/economía , Leuprolida/uso terapéutico , Masculino , Orquiectomía/economía , Neoplasias de la Próstata/economía , Neoplasias de la Próstata/patología , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento

RESUMEN

In the design of clinical trials, sample size determination is usually undertaken by statisticians and clinicians. It is rare for health economists to be involved in this aspect of trial design. However, there are a number of outcome changes that are of 'economic significance', and it is important for trial designers and funders to be aware of these before planning, funding and mounting a trial. In this paper we demonstrate through the use of three examples (prevention of osteoporosis, management of infertility, and endometriosis) how economics can be used to influence the size of a clinical trial. Trials that are too small or too large waste research resources; health economics can lead to more efficient trial designs.

Asunto(s)

Ensayos Clínicos como Asunto/economía , Tamaño de la Muestra , Adulto , Anciano , Análisis Costo-Beneficio , Danazol/economía , Endometriosis/tratamiento farmacológico , Femenino , Goserelina/economía , Humanos , Hidroclorotiazida/economía , Infertilidad Femenina/terapia , Osteoporosis/prevención & control , Proyectos de Investigación , Resultado del Tratamiento

RESUMEN

OBJECTIVE: To compare the costs of the various options presently available in Australia for treatment of advanced prostatic carcinoma by androgen deprivation. DESIGN: Forty patients underwent a bilateral orchidectomy for prostatic carcinoma during the 1990/91 financial year at the Princess Alexandra Hospital, Brisbane. The Yale Cost Model, as adapted for use in Australian case-mix projects, was used to derive a diagnosis related group (DRG) cost for this procedure. This was compared with the projected cost that would be incurred in treating patients with the various medical alternatives. To enable comparison, expenses were calculated assuming a mean duration of survival of two years. RESULTS: The average cost of a bilateral orchidectomy was $2869. This compared to $11,253 for goserelin and $12,329 for cyproterone acetate when used alone in treating a single patient. Flutamide is presently only approved for combination therapy with a luteinising hormone-releasing hormone agonist, and when used with goserelin an average cost of $16,148 per patient was projected. CONCLUSIONS: Bilateral orchidectomy is clearly the cheapest means of hormone manipulation for prostatic carcinoma. Unless the costs of alternative therapies are drastically reduced in Australia, their use is difficult to justify in other than exceptional circumstances. We believe their use should be restricted presently to patients who would otherwise require a bilateral orchidectomy and have an anticipated survival of less than six months.

Asunto(s)

Acetato de Ciproterona/economía , Costos de los Medicamentos , Goserelina/economía , Costos de la Atención en Salud , Orquiectomía/economía , Neoplasias de la Próstata/economía , Terapia Combinada/economía , Acetato de Ciproterona/uso terapéutico , Grupos Diagnósticos Relacionados/economía , Quimioterapia Combinada , Flutamida/economía , Flutamida/uso terapéutico , Goserelina/uso terapéutico , Humanos , Masculino , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/cirugía , Queensland